Ascendiant Capital Reiterates Rating on OTLK $OTLK
Key Points
- Ascendiant Capital now rates Outlook Therapeutics, Inc. ($OTLK) "buy" with a $10.00 target.
- The Street's average $OTLK price target is $5.50 (Buy).
- $OTLK last traded around $1.11.
Ascendiant Capital reiterated its rating on Outlook Therapeutics, Inc. ($OTLK) to a "buy" rating, with a price target of $10.00 in a recent research note.
Outlook Therapeutics, Inc. ($OTLK) Stock
Outlook Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.